MILPITAS, Calif., May 20, 2024
/PRNewswire/ -- Zepp Health Corporation ("Zepp" or the "Company")
(NYSE: ZEPP) today reported revenues of US$39.8 million; a basic and diluted
net loss per share of US$0.06;
and a basic and diluted net loss per ADS of US$0.23 for the first quarter ended
March 31, 2024; adjusted basic and diluted net
loss per share of US$0.05; and
adjusted basic and diluted net loss per ADS of
US$0.19. Each ADS represents four
Class A ordinary shares.
Mr. Wang 'Wayne' Huang, Chairman and CEO of Zepp, commented, "In
the first quarter of 2024, our revenue came broadly in
line with our guidance. Our gross margin performance
reached a record high, and our self-branded product sales
contributed over 85% of total revenues. Notably, the MAU of our
Zepp application has exceeded 10 million, marking an early success
of our transformation journey."
Wayne continued: "On the products front, we offer a diverse
range of series tailored to various market needs. Each series is
strategically positioned with a thorough understanding of its
competitors and targeted price ranges. We are delighted to observe
that our Balance and Active product line has gained more popularity
among consumers and KOLs due to the attractive designs and
innovative functionalities such as cutting-edge AI functions, a
wide range of health services and a diverse selection of watch
faces and app ecosystems. This has enabled us to position this
product line to a more premium market than before and generate
better gross margins. In May, we unveiled the new Amazfit Bip 5
Unity. Through the stainless-steel appearance and bigger screen, we
have brought many user-favorite software functions from our
mid-to-high-end product lines to Unity, and brought richer apps and
watch faces through Zepp OS 3.0 to unity, strengthening our
sub-$100 market competitiveness and
further expand our market share in emerging markets. We also
launched a new product line in May, Helio
Ring, which allows users who prefer not to wear watches
while sleeping to obtain 24-hour comprehensive health data
monitoring. This enhances recovery for athletes and provides
readiness analysis for general users, ensuring a holistic user
experience with both smartwatches and smart rings. We are the first
smartwatch brand to offer such a solution, placing us ahead of our
competitors. Our software, especially the proprietary operating
system, Zepp OS, has been upgraded to version 3.5, integrating the
large-model-based Zepp Flow AI system. This brings large model AI
interaction and messaging capabilities to our entire product line.
The rapid application and innovation of large model AI technology
provides our smartwatch products with opportunities to surpass
competitors, showcasing our company's execution and creativity
capabilities. Simultaneously, we've strategically invested in our
marketing initiatives, prioritizing digital campaigns and outdoor
advertising in influential global hubs. This includes prominent
placements like the Madrid airport
advertising campaign and sponsorship of events such as the recent
Rotterdam Marathon. We will launch more advertisements in major
global markets to amplify our market presence in coming quarters
and collaborate with major global channels like Decathlon, bringing
our innovative full-range products to users during this summer
sports craze to increase our sales for the second half of the year.
With exciting new product launches on the horizon, and supported by
our globalized research and management team, our confidence in our
roadmap and future opportunities has never been stronger. We are
confident that our strategic investments in expanding our brand,
enhancing our retail presence, and diversifying our product line
will drive growth and contribute to our long-term success."
Mr. Leon Deng, Zepp's Chief
Financial Officer, added, "The first quarter is traditionally a
slower season of us, with a significant decline of Xiaomi products
sales plus a more subdued new product launch window of our
self-branded products, leading to a revenue decline of this quarter
compared with last year. However, we continue to achieve a
historically high gross margin of 37%, a testament to the superior
performance of our self-branded products and a well-calibrated
product mix that included a higher proportion of new offerings and
reduced clearances. This accomplishment distinctly embodies our
strategic intent to prioritize profitability over scale. We
judiciously maintained our GAAP and adjusted operational
expenses at or below US$30 and US$28
million per quarter, consistent with since the second
quarter of last year and in line with our financial forecasts. Our
commitment to stringent discretionary spending controls remains
unwavering. We persistently pursued a cost-conscious approach while
continuing to invest strategically in R&D and marketing
initiatives to uphold our competitive edge."
Leon continued, "We have also maintained vigilant oversight of
our working capital throughout the first quarter. Despite a P&L
loss, we successfully sustained a positive operating cash flow for
the seventh consecutive quarter. In the first quarter of 2023,
we initiated a retirement of portions of our short and long-term
debt portfolio. Since the first quarter of 2023, we have
successfully retired US$46.7 million of debt. As our operating
cash flow continues to strengthen, we intend to do more in the
coming quarters. With a robust cash reserve of US$132.3 million, we are exceptionally
well-positioned to seize strategic investment opportunities and
capitalize on potential market expansions. As we progress through
2024, our dedication to operational excellence and strategic
foresight remains steadfast. We are resolute in our commitment to
enhancing the engagement and satisfaction of our users through
continuous innovation in product features and applications. In
the interim, we'll persist in our share repurchase program, a
tangible demonstration of management's unwavering confidence in the
company's trajectory."
First Quarter of 2024 Financial Summary
|
|
|
|
|
|
For the Three Months
Ended
|
Number
in millions, except for percentages
and
per- share/ADS amounts
|
|
Mar. 31, 2024
|
Mar. 31,
2023[1]
|
Revenue RMB
|
|
287.2
|
645.2
|
Revenue US$
|
|
39.8
|
93.9
|
Gross margin
|
36.8 %
|
15.9 %
|
Net loss RMB
|
|
(105.8)
|
(136.9)
|
Net loss US$
|
|
(14.6)
|
(19.9)
|
Adjusted EBIT
RMB[4]
|
|
(86.4)
|
(128.5)
|
Adjusted EBIT
US$
|
|
(12.0)
|
(18.7)
|
Net loss attributable
to Zepp Health Corporation
RMB
|
|
(105.5)
|
(136.7)
|
Adjusted net loss
attributable to Zepp Health
Corporation RMB[2]
|
|
(89.7)
|
(112.7)
|
Net loss
attributable to Zepp Health
Corporation
US$
|
|
(14.6)
|
(19.9)
|
Adjusted net
loss attributable to Zepp Health
Corporation US$
|
|
(12.4)
|
(16.4)
|
Basic/diluted
net loss per share RMB
|
|
(0.41)
|
(0.56)
|
Basic/diluted net loss
per ADS US$
|
(0.23)
|
(0.32)
|
Adjusted basic/diluted
net loss per share RMB[3]
|
|
(0.35)
|
(0.46)
|
Adjusted basic/diluted
net loss per ADS US$
|
(0.19)
|
(0.27)
|
Units shipped in
millions
|
1.2
|
3.5
|
|
|
|
|
|
[1] The US$
numbers in 2023 are referenced with the prior 6-K disclosures,
where translations from RMB to US$ are made at a rate
of RMB6.8676 to US$1.00, the effective noon buying rate on March
31, 2023 as set forth in the H.10 statistical release of
the
Federal Reserve Board.
|
[2] Adjusted
net income/(loss) attributable to Zepp Health Corporation
is a non-GAAP measure, which excludes share-based
compensation expenses. The tax effect from the adjustment of
the Share-based compensation expenses is nil. See
"Reconciliation
of GAAP and Non-GAAP Results" at the end of this press
release.
|
[3] Adjusted
diluted net income/(loss) is the abbreviation of adjusted net
income/(loss) attributable to Zepp Health
Corporation,
which is a non-GAAP measure and excludes share-based compensation
expenses attributable to Zepp Health Corporation, and
is
used as the numerator in computation of adjusted basic and diluted
net loss per ADS attributable to Zepp Health
Corporation.
|
[4] Adjusted
EBIT is a non-GAAP financial
measure, which is defined as net loss, excluding
(i) share-based
compensation
expenses, (ii) income tax (benefit)/
expense, (iii) interest income, (iv) interest expense.
|
|
First Quarter 2024 Financial
Results
Revenues
Revenues for the first quarter of 2024 reached US$39.8 million, a decrease by 55.5% from
the first quarter of 2023. The decrease was primarily due to
the decrease in the sales of Xiaomi wearable products, as well as
the decrease in sales of our self-branded products as we did not
launch any new self-branded products in the first quarter of
2024.
Total units shipped in the first quarter of 2024 decreased by
65.7% year-over-year to 1.2 million, compared with 3.5 million in
the first quarter of 2023.
Gross Margin
Gross margin in the first quarter of 2024 was 36.8%,
compared to 15.9% in the same period of 2023. We reached another
record-high quarterly gross margin since the third quarter of 2023,
supported by the strong performance of our self-branded products
and a more favourable product mix, with a higher proportion of new
products and a reduction in clearance sales, which typically have
lower margins.
Research and Development Expenses
Research and development expenses in the first quarter of
2024 were US$13.3 million,
a decrease by 18.4% year-over-year. This accounted for 33.5% of
revenues, compared to 18.3% for the same period in 2023. The
decrease was as a result of our refined research and development
approaches, as we consistently evaluated resource efficiency to
ensure maximum return on investment and productivity. We are
committed to investing in new technologies, including AI, to
maintain our competitive edge against our peers.
Selling and Marketing Expenses
Selling and marketing expenses in the first quarter of
2024 were US$10.7 million,
a decrease by 10.1% year-over-year. This accounted for 26.9% of
revenues, compared to 13.3% for the same period in 2023.
The decrease was primarily as a result of our consistent push on
retail profitability and channel mix improvement, which included
meticulous refinement of our retail channels and strategic staffing
arrangements across sales regions. Simultaneously, we've
strategically invested in our marketing initiatives, prioritizing
digital campaigns and outdoor advertising in influential global
hubs. We are committed to investing efficiently in marketing and
branding to ensure our sustained growth.
General and Administrative Expenses
General and administrative expenses were US$6.4 million in the
first quarter of 2024, a decrease by 7.9% year-over-year. This
accounted for 16.0% of revenues, compared with 7.7% in the same
period in 2023. The decrease in absolute value was largely
attributable to our personnel optimization initiative and strict
administrative expense control.
Operating Expenses
Total operating expenses for the first quarter of 2024 were
US$30.4 million, a decrease by
13.5% year-over-year. Adjusted operating expenses, which exclude
share-based compensation, were US$28.2 million. In the first quarter of
2024, we incurred one-off expenses of approximately US$0.5 million. We will maintain our
cost-conscious approach in the upcoming quarters. We expect our
operating expenses to either remain at current levels or decrease
further. Concurrently, we remain committed to investing in R&D
and marketing activities to ensure our long-term
competitiveness.
Operating Income/(Loss)
Operating loss for the first quarter of 2024 was
US$15.8 million, a decrease
by 24.6% year-over-year. The reduced loss was largely due to
the improved gross margin of our self-branded products and reduced
operating expenses.
Net Income/(Loss)
Net loss attributable to Zepp Health Corporation for the
first quarter of 2024 was US$14.6 million, a decrease by 22.8%
year-over-year. The adjusted net loss attributable to
Zepp Health Corporation, which excludes share-based compensation
expenses attributable to Zepp Health Corporation, was US$12.4 million, a decrease by 20.4%
year-over-year.
Liquidity and Capital Resources
As of March 31, 2024, the Company had cash and cash
equivalents and restricted cash of US$132.3 million, We have generated positive
cash flow from our operating activities for the
seventh consecutive quarter. We also successfully reduced our
total debt, including short-term and long-term bank borrowing
balance, by US$0.7 million in the
first quarter. We anticipate further reductions in our
debt level in the upcoming quarters.
The Company continued to manage its working capital and
inventory efficiently and recorded inventory levels of US$72.8 million as of March 31, 2024.This reached the lowest level
since June 30, 2019, marking a
decrease by 12.8% and 34.3% compared with December 31, 2023 and March 31, 2023, respectively. We will continue to
manage working capital tightly.
Share Repurchase Program Update
The Company announced in its third quarter 2021 earnings release
that the board had authorized a share repurchase program of up to
US$20 million through November
2022. On November 21, 2022, the
board authorized a 12-month extension of the Company's share
repurchase program. On November 20,
2023, the board further authorized the Company to extend its
share repurchase program for another 12 months. Pursuant to the
extended share repurchase program, the Company may repurchase its
shares in the form of American depositary shares and/or ordinary
shares through November 2024 with an
aggregate value equal to the remaining balance under the share
repurchase program. As of March 31, 2024, the Company had
used US$13.4 million to
repurchase 5,497,137 ADSs. The Company expects to fund
the repurchases under the extended share repurchase program out of
its existing cash balance.
Outlook
For the second quarter of 2024, the Company's management
currently expects net revenues to be between US$40 million and US$55 million, out of
which more than 90% are expected to be generated from
self-branded products. The new product Amazfit Helio Ring has
just been launched, and its contribution to revenues is
uncertain.
This outlook is based on current market conditions and reflects
the Company's current and preliminary estimates of market,
operating conditions and customer demand, which are all subject to
change.
Conference Call
The Company's management team will hold a conference call at
7:00 p.m. Eastern Time on Monday, May
20, 2024 (7:00 a.m. Beijing Time on May 21, 2024) to discuss financial results and
answer questions from investors and analysts. Listeners may access
the call by dialing:
US (Toll
Free):
|
+1-888-346-8982
|
International:
|
+1-412-902-4272
|
Mainland China (Toll
Free):
|
400-120-1203
|
Hong Kong (Toll
Free):
|
800-905-945
|
Hong Kong:
|
+852-3018-4992
|
Participants should dial in at least 10 minutes before the
scheduled start time and ask to be connected to the call for "Zepp
Health Corporation".
Additionally, a live and archived webcast of the conference call
will be available at http://ir.zepp.com.
A telephone replay will be available one hour after the call
until May 27, 2024 by
dialing:
US Toll
Free:
|
+1-877-344-7529
|
International:
|
+1-412-317-0088
|
Replay
Passcode:
|
9164265
|
About Zepp Health Corporation
Zepp Health Corporation (NYSE: ZEPP) is a global smart wearable
and health technology leader, empowering users to live their
healthiest lives by optimizing their health, fitness, and wellness
journeys through its leading consumer brands, Amazfit, Zepp
Clarity and Zepp Aura. Powered by its proprietary Zepp Digital
Management Platform, which includes the Zepp OS, AI chips,
biometric sensors and data algorithms, Zepp delivers cloud-based
24/7 actionable insights and guidance to help users attain their
wellness goals. To date, Zepp has shipped over 200 million units,
and its products are available in more than 90 countries and
regions. Founded in 2013 as Huami Corp., the Company changed its
name to Zepp Health Corporation in February 2021 to emphasize
its health focus with a name that resonates across languages and
cultures globally. Zepp has team members and offices across
globe, especially in Europe and USA regions.
Use of Non-GAAP Measures
We use adjusted net income/(loss), a non-GAAP financial measure,
in evaluating our operating results and for financial and
operational decision-making purposes. Adjusted operating expenses
represent operating expenses excluding share-based compensation
expenses. Adjusted operating income/(loss) represents operating
income/(loss) excluding share-based compensation
expenses. Adjusted EBIT represents net income/(loss) excluding
share-based compensation expenses, income tax (benefit)/expense,
interest income and interest expense. Adjusted net income/(loss)
represents net income/(loss) excluding share-based compensation
expenses, and such adjustment has no impact on income
tax. Adjusted net income/(loss) attributable to Zepp Health
Corporation is a non-GAAP measure, which excludes share-based
compensation expenses attributable to Zepp Health Corporation, and
is used as the numerator in computation of adjusted net
income/(loss) per share and per ADS attributable to Zepp Health
Corporation.
We believe that adjusted net income/(loss), adjusted EBIT and
adjusted net income/(loss) attributable to Zepp Health Corporation
help identify underlying trends in our business that could
otherwise be distorted by the effect of certain expenses that we
include in net income/(loss) and net income/(loss) attributable to
Zepp Health Corporation. We believe that adjusted net
income/(loss), adjusted EBIT and adjusted net income/(loss)
attributable to Zepp Health Corporation provides useful information
about our operating results, enhances the overall understanding of
our past performance and future prospects and allows for greater
visibility with respect to key metrics used by our management in
its financial and operational decision-making.
Adjusted net income/(loss), adjusted EBIT and adjusted net
income/(loss) attributable to Zepp Health Corporation, should not
be considered in isolation or construed as an alternative to net
income/(loss), basic and diluted net income/(loss) per share and
per ADS attributable to Zepp Health Corporation or any other
measure of performance or as an indicator of our operating
performance. Investors are encouraged to review the historical
non-GAAP financial measures to the most directly comparable GAAP
measures. Adjusted net income/(loss), adjusted EBIT and adjusted
net income/(loss) attributable to ordinary shareholders, presented
here may not be comparable to similarly titled measures presented
by other companies. Other companies may calculate similarly titled
measures differently, limiting their usefulness as comparative
measures to our data. We encourage investors and others to review
our financial information in its entirety and not rely on a single
financial measure.
Exchange Rate
The Company's business is primarily conducted in China. This announcement contains currency
conversions of RMB amounts into US$ solely for the convenience of
the reader. Unless otherwise noted, all translations from RMB to
US$ are made at a rate of RMB7.2203 to US$1.00, the effective noon buying rate on
March 29, 2024 as set forth in
the H.10 statistical release of the Federal Reserve Board. No
representation is made that the RMB amounts could have been, or
could be, converted, realized or settled into US$ at that rate on
March 29, 2024, or at any other
rate.
Safe Harbor Statement
This announcement contains forward-looking statements. These
statements are made under the "safe harbor" provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These
forward-looking statements can be identified by terminology such as
"will," "expects," "anticipates," "future," "intends," "plans,"
"believes," "estimates," "confident" and similar statements.
Statements that are not historical facts, including statements
about the Company's beliefs and expectations, are forward-looking
statements. Forward-looking statements involve inherent risks and
uncertainties. A number of factors could cause actual results to
differ materially from those contained in any forward-looking
statement, including but not limited to the following: the
cooperation with Xiaomi, the recognition of the Company's
self-branded products; the Company's growth strategies; trends and
competition in global wearable technology market; changes in the
Company's revenues and certain cost or expense accounting policies;
governmental policies relating to the Company's industry and
general economic conditions in China and the global. Further information
regarding these and other risks is included in the Company's
filings with the United States Securities and Exchange Commission.
All information provided in this press release and in the
attachments is as of the date of this press release, and the
Company undertakes no obligation to update any forward-looking
statement, except as required under applicable law.
For investor and media inquiries, please contact:
In China:
Zepp Health Corporation
Grace Yujia Zhang
Email: ir@zepp.com
Piacente Financial Communications
Tel: +86-10-6508-0677
Email: zepp@tpg-ir.com
Zepp Health
Corporation
|
UNAUDITED CONDENSED
CONSOLIDATED BALANCE SHEETS
|
(Amounts in
thousands of Renminbi ("RMB") and U.S. dollars
("US$")
|
except for number of
shares and per share data, or otherwise noted)
|
|
|
|
As of December
31,
|
|
As of
March 31,
|
|
|
2023
|
|
2024
|
|
|
RMB
|
|
RMB
|
|
US$
|
|
|
|
|
|
|
|
Assets
|
|
|
|
|
|
|
Current
assets:
|
|
|
|
|
|
|
Cash and cash
equivalents
|
|
949,036
|
|
895,823
|
|
124,070
|
Restricted
cash
|
|
48,282
|
|
59,265
|
|
8,208
|
Accounts receivable,
net
|
|
431,159
|
|
300,813
|
|
41,662
|
Amounts due from
related parties
|
|
61,098
|
|
23,841
|
|
3,302
|
Inventories,
net
|
|
602,688
|
|
525,785
|
|
72,820
|
Short-term
investments
|
|
36,586
|
|
43,169
|
|
5,979
|
Prepaid expenses and
other current assets
|
|
119,931
|
|
132,620
|
|
18,369
|
Total current
assets
|
|
2,248,780
|
|
1,981,316
|
|
274,410
|
|
|
|
|
|
|
|
Property, plant and
equipment, net
|
|
63,397
|
|
61,981
|
|
8,584
|
Intangible asset,
net
|
|
70,061
|
|
66,440
|
|
9,202
|
Goodwill
|
|
68,023
|
|
69,177
|
|
9,581
|
Long-term
investments
|
|
1,693,611
|
|
1,686,434
|
|
233,568
|
Deferred tax
assets
|
|
230,041
|
|
229,464
|
|
31,780
|
Amount due from related
parties, non-current
|
|
20,954
|
|
23,564
|
|
3,264
|
Other non-current
assets
|
|
68,852
|
|
59,629
|
|
8,259
|
Operating lease
right-of-use assets
|
|
48,412
|
|
34,292
|
|
4,749
|
Total
assets
|
|
4,512,131
|
|
4,212,297
|
|
583,397
|
Zepp Health
Corporation
|
UNAUDITED CONDENSED
CONSOLIDATED BALANCE SHEETS - CONTINUED
|
(Amounts in
thousands of Renminbi ("RMB") and U.S. dollars
("US$")
|
except for number of
shares and per share data, or otherwise noted)
|
|
|
|
As of December
31,
|
|
As of
March 31,
|
|
|
2023
|
|
2024
|
|
|
RMB
|
|
RMB
|
|
US$
|
|
|
|
|
|
|
|
Liabilities
|
|
|
|
|
|
|
Current
liabilities:
|
|
|
|
|
|
|
Accounts
payable
|
|
264,726
|
|
152,587
|
|
21,133
|
Advance from
customers
|
|
1,653
|
|
1,661
|
|
230
|
Amount due to related
parties
|
|
24,671
|
|
13,797
|
|
1,911
|
Accrued expenses and
other current liabilities
|
|
315,592
|
|
271,200
|
|
37,561
|
Income tax
payables
|
|
7,003
|
|
7,337
|
|
1,016
|
Notes
payable
|
|
475,629
|
|
434,099
|
|
60,122
|
Short-term bank
borrowings
|
|
12,000
|
|
275,000
|
|
38,087
|
Total current
liabilities
|
|
1,101,274
|
|
1,155,681
|
|
160,060
|
Deferred tax
liabilities
|
|
29,601
|
|
29,448
|
|
4,079
|
Long-term
borrowings
|
|
852,133
|
|
583,820
|
|
80,858
|
Other non-current
liabilities
|
|
1,916
|
|
1,916
|
|
265
|
Non-current operating
lease liabilities
|
|
22,697
|
|
21,513
|
|
2,980
|
Total
liabilities
|
|
2,007,621
|
|
1,792,378
|
|
248,242
|
Zepp Health
Corporation
|
UNAUDITED CONDENSED
CONSOLIDATED BALANCE SHEETS - CONTINUED
|
(Amounts in
thousands of Renminbi ("RMB") and U.S. dollars
("US$")
|
except for number of
shares and per share data, or otherwise noted)
|
|
|
|
As of December
31,
|
|
As of
March 31,
|
|
|
2023
|
|
2024
|
|
|
RMB
|
|
RMB
|
|
US$
|
|
|
|
|
|
|
|
Equity
|
|
|
|
|
|
|
Ordinary
shares
|
|
164
|
|
164
|
|
23
|
Additional paid-in
capital
|
|
1,750,580
|
|
1,766,355
|
|
244,637
|
Treasury
stock
|
|
(85,217)
|
|
(89,338)
|
|
(12,373)
|
Accumulated retained
earnings
|
|
730,731
|
|
625,207
|
|
86,590
|
Accumulated other
comprehensive income
|
|
96,318
|
|
105,828
|
|
14,657
|
Total Zepp Health
Corporation shareholders' equity
|
|
2,492,576
|
|
2,408,216
|
|
333,534
|
Noncontrolling
interest
|
|
11,934
|
|
11,703
|
|
1,621
|
Total
equity
|
|
2,504,510
|
|
2,419,919
|
|
335,155
|
Total liabilities
and equity
|
|
4,512,131
|
|
4,212,297
|
|
583,397
|
Zepp Health
Corporation
|
UNAUDITED CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS
|
(Amounts in
thousands of Renminbi ("RMB") and U.S. dollars
("US$")
|
except for number of
shares and per share data, or otherwise noted)
|
|
|
|
For the Three Months
Ended March 31,
|
|
|
2023
|
|
2024
|
|
|
RMB
|
|
RMB
|
|
US$
|
|
|
|
|
|
|
|
Revenues
|
|
645,183
|
|
287,231
|
|
39,781
|
Cost of
revenues
|
|
(542,338)
|
|
(181,557)
|
|
(25,145)
|
Gross
profit
|
|
102,845
|
|
105,674
|
|
14,636
|
Operating
expenses:
|
|
|
|
|
|
|
Selling and
marketing
|
|
(85,978)
|
|
(77,313)
|
|
(10,708)
|
General and
administrative
|
|
(49,901)
|
|
(45,961)
|
|
(6,366)
|
Research and
development
|
|
(117,874)
|
|
(96,136)
|
|
(13,315)
|
Total operating
expenses
|
|
(253,753)
|
|
(219,410)
|
|
(30,389)
|
Operating
loss
|
|
(150,908)
|
|
(113,736)
|
|
(15,753)
|
Other income and
expenses:
|
|
|
|
|
|
|
Interest
income
|
|
4,133
|
|
7,277
|
|
1,008
|
Interest
expense
|
|
(13,318)
|
|
(10,371)
|
|
(1,436)
|
Other
(expense)/income, net
|
|
(1,985)
|
|
489
|
|
68
|
Gain
from fair value change of long-term
investments
|
|
3,127
|
|
15,118
|
|
2,094
|
Investment
income
|
|
234
|
|
-
|
|
-
|
Loss before income
tax and loss from equity
method investments
|
|
(158,717)
|
|
(101,223)
|
|
(14,019)
|
Income tax
benefits/(expenses)
|
|
24,734
|
|
(514)
|
|
(71)
|
Loss before income
from equity method investments
|
|
(133,983)
|
|
(101,737)
|
|
(14,090)
|
Net loss from equity
method investments
|
|
(2,931)
|
|
(4,018)
|
|
(556)
|
Net
loss
|
|
(136,914)
|
|
(105,755)
|
|
(14,646)
|
Less: Net loss
attributable to noncontrolling interest
|
|
(194)
|
|
(231)
|
|
(32)
|
Net
loss attributable to Zepp Health
Corporation
|
|
(136,720)
|
|
(105,524)
|
|
(14,614)
|
Net loss per share
attributable to Zepp Health Corporation
|
|
|
|
|
|
|
Basic loss
per ordinary share
|
|
(0.56)
|
|
(0.41)
|
|
(0.06)
|
Diluted loss
per ordinary share
|
|
(0.56)
|
|
(0.41)
|
|
(0.06)
|
|
|
|
|
|
|
|
Net
loss per ADS (4 ordinary shares equal to 1
ADS)
|
|
|
|
|
|
|
ADS – basic
|
|
(2.23)
|
|
(1.63)
|
|
(0.23)
|
ADS –
diluted
|
|
(2.23)
|
|
(1.63)
|
|
(0.23)
|
|
|
|
|
|
|
|
Weighted average
number of shares used in computing net loss per
share
Ordinary share –
basic
|
|
245,133,616
|
|
259,525,679
|
|
259,525,679
|
Ordinary share –
diluted
|
|
245,133,616
|
|
259,525,679
|
|
259,525,679
|
Zepp Health
Corporation
|
Reconciliation of
GAAP and Non-GAAP Results
|
(Amounts in
thousands of Renminbi ("RMB") and U.S. dollars
("US$")
|
except for number of
shares and per share data, or otherwise noted)
|
|
|
|
For the Three Months
Ended March 31,
|
|
|
2023
|
|
2024
|
|
|
RMB
|
|
RMB
|
|
US$
|
|
|
|
|
|
|
|
Total operating
expenses
|
|
(253,753)
|
|
(219,410)
|
|
(30,389)
|
Share-based
compensation expenses[2]
|
|
23,992
|
|
15,775
|
|
2,186
|
Total adjusted
operating expenses
|
|
(229,761)
|
|
(203,635)
|
|
(28,203)
|
|
|
|
|
|
|
|
Operating
loss
|
|
(150,908)
|
|
(113,736)
|
|
(15,753)
|
Share-based
compensation expenses
|
|
23,992
|
|
15,775
|
|
2,186
|
Adjusted operating
loss
|
|
(126,916)
|
|
(97,961)
|
|
(13,567)
|
|
|
|
|
|
|
|
Net loss
|
|
(136,914)
|
|
(105,755)
|
|
(14,646)
|
Share-based
compensation expenses
|
|
23,992
|
|
15,775
|
|
2,186
|
Income tax
(benefits)/expenses
|
|
(24,734)
|
|
514
|
|
71
|
Interest
income
|
|
(4,133)
|
|
(7,277)
|
|
(1,008)
|
Interest
expense
|
|
13,318
|
|
10,371
|
|
1,436
|
Adjusted
EBIT
|
|
(128,471)
|
|
(86,372)
|
|
(11,961)
|
|
|
|
|
|
|
|
Net
loss attributable to Zepp Health
Corporation
|
|
(136,720)
|
|
(105,524)
|
|
(14,614)
|
Share-based
compensation expenses
|
|
23,992
|
|
15,775
|
|
2,186
|
Adjusted net loss
attributable to Zepp Health
Corporation[2]
|
|
(112,728)
|
|
(89,749)
|
|
(12,428)
|
|
Adjusted net loss
per share attributable to
Zepp Health Corporation
|
|
|
|
|
|
|
Adjusted basic loss per
ordinary share
|
|
(0.46)
|
|
(0.35)
|
|
(0.05)
|
Adjusted diluted loss
per ordinary share
|
|
(0.46)
|
|
(0.35)
|
|
(0.05)
|
|
|
|
|
|
|
|
Adjusted net
loss per ADS (4 ordinary shares equal to 1
ADS)
|
|
|
|
|
|
|
ADS – basic
|
|
(1.84)
|
|
(1.38)
|
|
(0.19)
|
ADS –
diluted
|
|
(1.84)
|
|
(1.38)
|
|
(0.19)
|
|
|
|
|
|
|
|
Weighted average
number of shares used in computing
adjusted net loss per share
|
|
|
|
|
|
|
Ordinary share –
basic
|
|
245,133,616
|
|
259,525,679
|
|
259,525,679
|
Ordinary share –
diluted
|
|
245,133,616
|
|
259,525,679
|
|
259,525,679
|
|
|
|
|
|
|
|
Share-based
compensation expenses included
are follows:
|
|
|
|
|
|
|
Selling and
marketing
|
|
1,155
|
|
1,694
|
|
235
|
General and
administrative
|
|
10,783
|
|
7,427
|
|
1,029
|
Research and
development
|
|
12,054
|
|
6,654
|
|
922
|
Total
|
|
23,992
|
|
15,775
|
|
2,186
|
View original
content:https://www.prnewswire.com/news-releases/zepp-health-corporation-reports-first-quarter-2024-unaudited-financial-results-302150195.html
SOURCE Zepp Health Corp.